Developing New Medicines for Cough

Cough

Chronic cough affects more than 2.5 million people in the U.S. and has no approved therapies.

Learn more >

Bradanicline

Attenua’s lead compound is a neuronal nicotinic receptor (NNR) agonist currently in Phase 2 clinical development.

Learn more >